These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 39073562)
1. Three-month outcomes of treatment with faricimab or aflibercept for neovascular age-related macular degeneration: a propensity score matching study in a Japanese population. Fukuda Y; Notomi S; Shiose S; Maehara Y; Kiyohara K; Fujiwara K; Hashimoto S; Kano K; Ishikawa K; Hisatomi T; Sonoda KH Graefes Arch Clin Exp Ophthalmol; 2024 Jul; ():. PubMed ID: 39073562 [TBL] [Abstract][Full Text] [Related]
2. Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab. Raimondi R; Falfeli T; Bogdanova-Bennet A; Varma D; Habib M; Kotagiri A; Steel DH; Grinton M Ophthalmol Retina; 2024 Jun; 8(6):537-544. PubMed ID: 38040055 [TBL] [Abstract][Full Text] [Related]
3. Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration. Kishi M; Miki A; Kamimura A; Okuda M; Matsumiya W; Imai H; Kusuhara S; Nakamura M J Clin Med; 2023 Aug; 12(15):. PubMed ID: 37568546 [TBL] [Abstract][Full Text] [Related]
4. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Kataoka K; Itagaki K; Hashiya N; Wakugawa S; Tanaka K; Nakayama M; Yamamoto A; Mukai R; Honjyo J; Maruko I; Kawai M; Miyara Y; Terao N; Wakatsuki Y; Onoe H; Mori R; Koizumi H; Sekiryu T; Iida T; Okada AA; Graefes Arch Clin Exp Ophthalmol; 2024 Jan; 262(1):43-51. PubMed ID: 37668741 [TBL] [Abstract][Full Text] [Related]
5. Short-Term Comparison of Switching to Brolucizumab or Faricimab from Aflibercept in Neovascular AMD Patients. Kin A; Mizukami T; Ueno S; Mishima S; Shimomura Y Medicina (Kaunas); 2024 Jul; 60(7):. PubMed ID: 39064598 [No Abstract] [Full Text] [Related]
6. Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration. Maruyama-Inoue M; Yanagi Y; Inoue T; Kadonosono K Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):589-599. PubMed ID: 37750953 [TBL] [Abstract][Full Text] [Related]
7. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial. Mori R; Honda S; Gomi F; Tsujikawa A; Koizumi H; Ochi H; Ohsawa S; Okada AA; Jpn J Ophthalmol; 2023 May; 67(3):301-310. PubMed ID: 37039948 [TBL] [Abstract][Full Text] [Related]
8. Short-Term Outcomes of 3 Monthly intravitreal Faricimab On Different Subtypes of Neovascular Age-Related Macular Degeneration. Tanaka A; Hata M; Tsuchikawa M; Ueda-Arakawa NU; Tamura H; Miyata M; Takahashi A; Kido A; Muraoka Y; Miyake M; Ooto S; Tsujikawa A Clin Ophthalmol; 2024; 18():507-516. PubMed ID: 38405104 [TBL] [Abstract][Full Text] [Related]
9. Visual and Anatomical Outcomes After Initial Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration in Patients with Prior Treatment History. Inoda S; Takahashi H; Takahashi R; Hashimoto Y; Yoshida H; Takahashi H; Takayama T; Kawashima H; Yanagi Y Ophthalmol Ther; 2023 Oct; 12(5):2703-2712. PubMed ID: 37531030 [TBL] [Abstract][Full Text] [Related]
10. TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration. Khanani AM; Guymer RH; Basu K; Boston H; Heier JS; Korobelnik JF; Kotecha A; Lin H; Silverman D; Swaminathan B; Willis JR; Yoon YH; Quezada-Ruiz C Ophthalmol Sci; 2021 Dec; 1(4):100076. PubMed ID: 36246941 [TBL] [Abstract][Full Text] [Related]
11. One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration. Matsumoto H; Hoshino J; Nakamura K; Akiyama H Jpn J Ophthalmol; 2024 Mar; 68(2):83-90. PubMed ID: 38244172 [TBL] [Abstract][Full Text] [Related]
12. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Wong TY; Haskova Z; Asik K; Baumal CR; Csaky KG; Eter N; Ives JA; Jaffe GJ; Korobelnik JF; Lin H; Murata T; Ruamviboonsuk P; Schlottmann PG; Seres AI; Silverman D; Sun X; Tang Y; Wells JA; Yoon YH; Wykoff CC; Ophthalmology; 2024 Jun; 131(6):708-723. PubMed ID: 38158159 [TBL] [Abstract][Full Text] [Related]